— Gilead Sciences (NYSE: GILD) reported third-quarter 2019 earnings of $1.75 per share, vs. $1.74 per share expected.
— Total revenue remained flat at $5.60 billion, vs. $5.61 billion expected. Total product sales were flat at 5.5 billion.
— Narrowed full year 2019 guidance on sales to $21.8-22.1 billion, from earlier esimtate of $21.6-22.1 billion.
— GILD shares have been trading sideways since the beginning of this year. The stock has so far declined 3% this year.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
AbbVie Q1 2025 adjusted earnings increase on 8% revenue growth; beat estimates
Biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) announced first-quarter 2025 financial results, reporting an increase in revenue and adjusted earnings. The company reported worldwide net revenues of $13.3 billion for the
Colgate-Palmolive (CL) Q1 2025 Earnings: Key financials and quarterly highlights
Colgate-Palmolive Company (NYSE: CL) reported its first quarter 2025 earnings results today. Net sales decreased 3.1% year-over-year to $4.9 billion. Organic sales growth was 1.4%. Net income attributable to Colgate-Palmolive Company rose
Meta Platforms (META) set to report Q1 earnings. Here’s what to expect
After integrating artificial intelligence into its products, Meta Platforms, Inc. (NASDAQ: META) is investing heavily in the metaverse project. Yet, the tech giant has maintained healthy cash flows and consistently
